Patent ID: 11866518
Assignee: BICYCLETX LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 3:
4. The peptide ligand as defined in claim 1, wherein said peptide ligand comprises an amino acid sequence selected from:
A-(SEQ ID NO: 141)-A (hereinafter referred to as Example 196);
A-(SEQ ID NO: 142)-A (hereinafter referred to as Example 197);
A-(SEQ ID NO: 143)-A (hereinafter referred to as Example 198);
A-(SEQ ID NO: 144)-A (hereinafter referred to as Example 199);
DEQHHE-(SEQ ID NO: 144)-A (hereinafter referred to as Example 209);
SNATKQ-(SEQ ID NO: 144)-A (hereinafter referred to as Example 210);
GNIKKS-(SEQ ID NO: 144)-A (hereinafter referred to as Example 211);
A-(SEQ ID NO: 144)-DPSSKQA (hereinafter referred to as Example 212);
A-(SEQ ID NO: 144)-YDNEMSA (hereinafter referred to as Example 213);
SEAQET-(SEQ ID NO: 144) (hereinafter referred to as Example 214);
SPTEPP-(SEQ ID NO: 144) (hereinafter referred to as Example 215);
(SEQ ID NO: 144)-EPETGQ (hereinafter referred to as Example 216);
NRSPSE-(SEQ ID NO: 144) (hereinafter referred to as Example 217);
Ac-(SEQ ID NO: 144) (hereinafter referred to as Example 218);
R7-(SEQ ID NO: 144) (hereinafter referred to as Example 219);
A-(SEQ ID NO: 144)-EPETGQA (hereinafter referred to as Example 221);
(SEQ ID NO: 144)-GDMSVS (hereinafter referred to as Example 222);
(SEQ ID NO: 144)-YDNEMS (hereinafter referred to as Example 223);
(SEQ ID NO: 144)-APDHLP (hereinafter referred to as Example 224);
(SEQ ID NO: 144)-DPSSKQ (hereinafter referred to as Example 226);
(SEQ ID NO: 144)-ANSEFE (hereinafter referred to as Example 227);
(SEQ ID NO: 144)-GAGESS (hereinafter referred to as Example 228);
DHD-(SEQ ID NO: 145)-A (hereinafter referred to as Example 200);
ADG-(SEQ ID NO: 146)-A (hereinafter referred to as Example 201);
TLP-(SEQ ID NO: 147)-A (hereinafter referred to as Example 202);
SQE-(SEQ ID NO: 148)-A (hereinafter referred to as Example 203);
AET-(SEQ ID NO: 149)-A (hereinafter referred to as Example 204);
A-(SEQ ID NO: 150)-DPN (hereinafter referred to as Example 205);
A-(SEQ ID NO: 151)-API (hereinafter referred to as Example 206);
A-(SEQ ID NO: 152)-ANT (hereinafter referred to as Example 207);
A-(SEQ ID NO: 153)-FAE (hereinafter referred to as Example 208);
AND-(SEQ ID NO: 154)-A (hereinafter referred to as Example 220); and
ERN-(SEQ ID NO: 155)-A (hereinafter referred to as Example 225);, wherein R7 represents, , or a pharmaceutically acceptable salt thereof.